-
公开(公告)号：US10406161B2
公开(公告)日：2019-09-10
申请号：US16144614
申请日：2018-09-27
发明人： Kaoxiang Sun , Rongcai Liang , Qilin Wang , Wenyan Wang , Wanhui Liu , Youxin Li
摘要： A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
-
公开(公告)号：US11110094B2
公开(公告)日：2021-09-07
申请号：US16525502
申请日：2019-07-29
发明人： Kaoxiang Sun , Rongcai Liang , Oilin Wang , Wenyan Wang , Wanhui Liu , Youxin Li
摘要： A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
-
公开(公告)号：US20170056407A1
公开(公告)日：2017-03-02
申请号：US15347365
申请日：2016-11-09
发明人： Kaoxiang Sun , Rongcai Liang , Qilin Wang , Wenyan Wang , Wanhui Liu , Youxin Li
IPC分类号： A61K31/519 , A61K9/00 , A61K9/16
CPC分类号： A61K31/519 , A61K9/0019 , A61K9/14 , A61K9/16 , A61K9/1647 , A61K9/19 , A61K9/4858 , A61K9/5031 , A61K9/5089 , A61K47/34
摘要： A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
摘要翻译： 提供了利培酮缓释微球制剂。 微球制剂包括利培酮或9-羟基利培酮或其盐，以及具有第一未封端丙交酯 - 乙交酯共聚物和第二未封端丙交酯 - 乙交酯共聚物的聚合物共混物，其中第一未封端丙交酯 - 乙交酯共聚物是具有高的共聚物 特性粘度和第二未封端丙交酯 - 乙交酯共聚物是具有低特性粘度的共聚物。 根据本公开实施方案的缓释微球制剂适用于具有改进的稳定性的大规模工业化生产，其体内释放行为在长期储存后不会改变。
-
公开(公告)号：US20190022098A1
公开(公告)日：2019-01-24
申请号：US16144614
申请日：2018-09-27
发明人： Kaoxiang Sun , Rongcai Liang , Qilin Wang , Wenyan Wang , Wanhui Liu , Youxin Li
IPC分类号： A61K31/519 , A61K9/19 , A61K9/50 , A61K9/00
CPC分类号： A61K31/519 , A61K9/0019 , A61K9/14 , A61K9/16 , A61K9/1647 , A61K9/19 , A61K9/4858 , A61K9/5031 , A61K9/5089 , A61K47/34
摘要： A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
-
公开(公告)号：US10098882B2
公开(公告)日：2018-10-16
申请号：US15347365
申请日：2016-11-09
发明人： Kaoxiang Sun , Rongcai Liang , Qilin Wang , Wenyan Wang , Wanhui Liu , Youxin Li
摘要： A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
-
公开(公告)号：US20160331752A1
公开(公告)日：2016-11-17
申请号：US15217696
申请日：2016-07-22
发明人： Kaoxiang Sun , Rongcai Liang , Qilin Wang , Wenyan Wang , Wanhui Liu , Youxin Li
IPC分类号： A61K31/519 , A61K9/48 , A61K9/00 , A61K9/50
CPC分类号： A61K31/519 , A61K9/0019 , A61K9/14 , A61K9/16 , A61K9/1647 , A61K9/19 , A61K9/4858 , A61K9/5031 , A61K9/5089 , A61K47/34
摘要： A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
摘要翻译： 提供了利培酮缓释微球制剂。 微球制剂包括利培酮或9-羟基利培酮或其盐，以及具有第一未封端丙交酯 - 乙交酯共聚物和第二未封端丙交酯 - 乙交酯共聚物的聚合物共混物，其中第一未封端丙交酯 - 乙交酯共聚物是具有高的共聚物 特性粘度和第二未封端丙交酯 - 乙交酯共聚物是具有低特性粘度的共聚物。 根据本公开实施方案的缓释微球制剂适用于具有改进的稳定性的大规模工业化生产，其体内释放行为在长期储存后不会改变。
-
公开(公告)号：US09532991B2
公开(公告)日：2017-01-03
申请号：US15217696
申请日：2016-07-22
发明人： Kaoxiang Sun , Rongcai Liang , Qilin Wang , Wenyan Wang , Wanhui Liu , Youxin Li
IPC分类号： A61K9/50 , A61K31/519 , A61K9/48 , A61K9/00 , A61K9/16
CPC分类号： A61K31/519 , A61K9/0019 , A61K9/14 , A61K9/16 , A61K9/1647 , A61K9/19 , A61K9/4858 , A61K9/5031 , A61K9/5089 , A61K47/34
摘要： A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
摘要翻译： 提供了利培酮缓释微球制剂。 微球制剂包括利培酮或9-羟基利培酮或其盐，以及具有第一未封端丙交酯 - 乙交酯共聚物和第二未封端丙交酯 - 乙交酯共聚物的聚合物共混物，其中第一未封端丙交酯 - 乙交酯共聚物是具有高的共聚物 特性粘度和第二未封端丙交酯 - 乙交酯共聚物是具有低特性粘度的共聚物。 根据本公开实施方案的缓释微球制剂适用于具有改进的稳定性的大规模工业化生产，其体内释放行为在长期储存后不会改变。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.019 秒)
